Contract HHSO100201300006I
Amgen USA Inc · Department Of Health And Human Services · September 19, 2013
Amgen USA Inc was awarded a federal contract by Department Of Health And Human Services (Office Of Assistant Secretary For Preparedness And Response) on September 19, 2013 for $500,000 of work in biological product (except diagnostic) manufacturing. It was awarded under full and open competition. The contract has been modified 2 times since the base award It uses firm fixed-price contract pricing. The most recent modification was on July 11, 2018. If all options are exercised, the contract could reach $814.65 million.
Contract details
- PIID
- HHSO100201300006I
- Award type
- —
- Pricing
- Firm Fixed Price
- Set-aside
- No Set Aside Used.
- Competition
- Full And Open Competition
- NAICS
- 325414 · Biological Product (Except Diagnostic) Manufacturing
- Product / service
- R&D- Medical: Biomedical (Advanced Development)
- First action
- September 19, 2013
- Latest action
- July 11, 2018
Description
IGF::OT::IGF
Modification timeline
-
July 11, 2018Mod 2$0
-
September 26, 2013Mod 1$0
-
September 19, 2013Base award$500.0K
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Bio-Rad Laboratories, Inc. | Department Of Health And Human Services | March 31, 2026 | $20.6K |
| Georgia Tech Research Corp | Department Of Health And Human Services | March 28, 2026 | $145.8K |
| Seqirus Inc | Department Of Health And Human Services | March 25, 2026 | $23.7K |
| Seqirus Inc | Department Of Health And Human Services | March 24, 2026 | $0 |
| Battelle Memorial Institute | Department Of Health And Human Services | March 19, 2026 | $2.80M |
| Sanofi Vaccines Us Inc. | Department Of Health And Human Services | March 19, 2026 | $53.21M |
Top contractors in NAICS 325414
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Pfizer Inc | 3 | $15.27B |
| 2 | Sanofi Vaccines Us Inc. | 606 | $9.38B |
| 3 | Regeneron Pharmaceuticals Inc | 1 | $5.57B |
| 4 | Merck Sharp & Dohme Corp. | 56 | $3.99B |
| 5 | Emergent Biodefense Operations Lansing Llc | 16 | $3.34B |
| 6 | Merck Sharp & Dohme Llc | 15 | $3.33B |
| 7 | Pfizer Inc. | 25 | $3.11B |
| 8 | Glaxosmithkline Holdings (Americas) Inc. | 109 | $2.24B |
| 9 | Modernatx, Inc. | 1 | $1.75B |
| 10 | Bavarian Nordic A/S | 1 | $1.01B |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract HHSO100201300006I?
Contract HHSO100201300006I is a federal contract awarded to Amgen USA Inc by Department Of Health And Human Services on September 19, 2013 for $500,000 of work classified under BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING. It has been modified 2 times since the base award.
Who won contract HHSO100201300006I?
Amgen USA Inc won contract HHSO100201300006I from Department Of Health And Human Services.
How much is contract HHSO100201300006I worth?
Contract HHSO100201300006I has obligated $500,000 to date, with a total potential value of $814.65 million if all options are exercised.